All products of ISA Pharmaceuticals are synthetic immunotherapeutics based on a proprietary development platform and address cancer and persistent viral infections.

The primary focus of the company is the development of its ISA101 immunotherapeutic for cervical cancer. Concurrently, pre-malignant HPV-related disease indications – including vulvar and anal intra-epithelial neoplasias (VIN, AIN) – are also being evaluated in preclinical and clinical studies and have generated impressive results. In 2013, the company has initiated a clinical study of ISA101 in patients with advanced or recurrent cervical cancer and a Phase I/II study of ISA101 in patients with AIN.

Building on the vast amount of experience and know-how in inducing potent T-cell responses against cancer and infectious diseases, and in leveraging recent technological advancements in next-generation sequencing of DNA and RNA, bioinformatics and parallel peptide synthesis, ISA has begun to develop on-demand, personalized SLP® immunotherapies called MyISA®. These therapies are specifically designed for each individual patient, and therefore only effective for that patient and nobody else.

Moreover, ISA Pharmaceuticals develops an immunotherapeutic derived from the human testis antigen PRAME (PReferentially expressed Antigen in Melanoma), which can be used to treat different types of cancer that have significantly increased expression of PRAME, such as lung cancer, melanoma, breast cancer, AML and neuroblastoma. The compound called ISA203 consists of synthetic long peptides (SLP®) conjugated to ISA’s proprietary adjuvant AMPLIVANT®. It is currently in preclinical development.

ISA Pharmaceutical´s product candidate ISA204 is a combination of selected Synthetic Long Peptides (SLP®s) derived from conserved regions of hepatitis B antigens with ISA’s AMPLIVANT® adjuvant technology. It is designed as an effective immunotherapy for the entire patient population, and avoids virus escape mutants by inducing a T cell response against multiple conserved viral antigens. The program is at the discovery stage.